



TTK Healthcare LIMITED

TTKHC:SEC:SL:227:24

August 02, 2024

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

Re : Outcome of the Board Meeting - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, we provide below the outcome of the meeting of the Board of Directors held today (i.e.) **August 02, 2024**:

1. **Unaudited Financial Results along with Limited Review Report for the First Quarter ended June 30, 2024:**

The Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the First Quarter ended June 30, 2024, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on August 01, 2024 and approved by the Board of Directors, in their meeting held today, are attached herewith as **Annexure–A**.

2. **Reconstitution of the various Committees of the Board, w.e.f. August 22, 2024:**

Consequent to conclusion of the term of appointment of Dr Vandana R Walvekar and Mr Girish Rao as the Independent Directors of the Company on August 21, 2024, the various Committees of the Board has been reconstituted, w.e.f. August 22, 2024, as detailed below:

a) **Audit Committee**

Name of the Director	Category	Position
Mr S Balasubramanian	Independent Director	Chairman
Mr K Shankaran	Non-Independent Director	Member
Mr V Ranganathan	Independent Director	Member
Mr N Ramesh Rajan	Independent Director	Member

b) **Nomination and Remuneration Committee**

Name of the Director	Category	Position
Mr N Ramesh Rajan	Independent Director	Chairman
Mr K Shankaran	Non-Independent Director	Member
Mr S Balasubramanian	Independent Director	Member
Mr Murali Neelakantan	Independent Director	Member

..... 2

CAS



TTK Healthcare LIMITED

2

c) **Stakeholders Relationship Committee**

Name of the Director	Category	Position
Mr K Shankaran	Non-Independent Director	Chairman
Mr R K Tulshan	Non-Independent Director	Member
Mr V Ranganathan	Independent Director	Member

d) **Corporate Social Responsibility Committee**

Name of the Director	Category	Position
Mr T T Raghunathan	Executive Director	Chairman
Mr R K Tulshan	Non-Independent Director	Member
Mr K Shankaran	Non-Independent Director	Member
Mr Murali Neelakantan	Independent Director	Member

This intimation is also made available on the website of the Company at www.ttkhealthcare.com.

3. **Amendment to the Policy for Disclosure of Events or Information**

A copy of the said amended policy is available at the website of the Company at www.ttkhealthcare.com.

4. **Contact details for determining materiality of an event or information**

The contact details of the Key Managerial Personnel (KMP) authorised under Regulation 30(5) of the SEBI (LORD), Regulations, 2015 are given below:-

S. No.	Name of the KMP	Designation	Contact Details	
			Phone	Email IDs
1.	Mr. S Kalyanaraman	Wholetime Director & Chief Executive Officer	+91 44 28116106	skr@ttkhealthcare.com
2.	Mr. B V K Durga Prasad	President – Finance (CFO)	+91 44 28116106	dp@ttkhealthcare.com
3.	Ms. Gowry A Jaishankar	DGM – Legal & Company Secretary	+91 44 28116106	gowry@ttkhealthcare.com

The Board Meeting commenced at 12 noon and concluded at 01:00 p.m.

Kindly take the above information / documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(GOWRY A JAISHANKAR)
DGM – Legal & Company Secretary

Encl.: a/a


TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the year ended
		(30/06/2024)	(31/03/2024)	(30/06/2023)	(31/03/2024)
		Unaudited	Audited	Unaudited	Audited
I.	Revenue from Operations	20,790.21	18,105.63	20,212.35	75,279.38
II.	Other Income	1,702.64	1,605.83	1,461.34	6,260.71
III.	Total Income (I + II)	22,492.85	19,711.46	21,673.69	81,540.09
IV.	Expenses:				
	(a) Cost of materials consumed	4,944.61	4,467.88	4,523.01	17,325.68
	(b) Purchase of Stock-in-trade	4,559.84	4,023.64	4,385.20	17,559.39
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(151.17)	(93.01)	(401.38)	(1,059.92)
	(d) Employee benefits expense	3,836.08	3,224.17	3,444.13	13,284.00
	(e) Finance Costs	85.79	92.96	85.99	275.55
	(f) Depreciation and Amortization Expense	205.14	331.95	315.58	1,305.87
	(g) Other Expenses	6,910.18	5,241.24	7,257.30	24,437.49
	Total Expenses (IV)	20,390.47	17,288.83	19,609.83	73,128.06
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	2,102.38	2,422.63	2,063.86	8,412.03
VI.	Exceptional Items (Ref. Note. 3 below)	1,977.05	-	-	-
VII.	Profit / (Loss) before Tax (V - VI)	4,079.43	2,422.63	2,063.86	8,412.03
VIII.	Tax Expense:				
	(1) Current Tax	935.00	590.00	530.00	2,210.00
	(2) Deferred Tax	(13.08)	5.43	(33.05)	(82.16)
IX.	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	3,157.51	1,827.20	1,566.91	6,284.19
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-
XI.	Tax Expense from Discontinued Operations	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	3,157.51	1,827.20	1,566.91	6,284.19
XIV.	Other Comprehensive Income:				
	(A) (i) Items that will not be reclassified subsequently to profit or loss	203.42	(232.69)	98.18	(143.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(13.95)	32.63	(6.02)	26.22
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period] including Human Pharma operations Discontinued	3,346.98	1,627.14	1,659.07	6,166.51

	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)	-	-	-	98,237.43
XVI.	Earnings per Equity Share (For Continuing Operations):				
(1)	Basic (in Rs.)	22.35	12.93	11.09	44.47
(2)	Diluted (in Rs.)	22.35	12.93	11.09	44.47
XVII.	Earnings per Equity Share (For Discontinued Operations):				
(1)	Basic (in Rs.)	-	-	-	-
(2)	Diluted (in Rs.)	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):				
(1)	Basic (in Rs.)	22.35	12.93	11.09	44.47
(2)	Diluted (in Rs.)	22.35	12.93	11.09	44.47

Notes:

- (1) The above financial results for the First Quarter ended June 30, 2024 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on August 01, 2024 and approved by the Board of Directors of the Company at its meeting held on August 2, 2024 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) During the Quarter, the Company has sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2300 lakhs and the profit on sale amounting to Rs.1977.05 lakhs (Net) has been considered in the above results.
- (4) Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 20-21 and proposes to take further appropriate action after the Rules are made applicable.
- (5) The figures for the Quarter ended 31st March, 2024 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) The full financial results for the First Quarter ended June 30, 2024 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : August 02, 2024



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER ENDED JUNE 30, 2024

(Rs. in lakhs)


Sl. No.	Particulars	For the Quarter ended			For the year ended
		(30/06/2024)	(31/03/2024)	(30/06/2023)	(31/03/2024)
		Unaudited	Audited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)				
(a)	Animal Welfare	3,111.19	2,899.39	2,723.78	11,551.45
(b)	Consumer Products	7,314.28	5,052.59	7,117.66	23,237.33
(c)	Medical Devices	2,457.87	1,988.23	2,221.10	8,049.04
(d)	Protective Devices	4,628.83	4,832.52	5,146.94	19,986.46
(e)	Foods	3,270.01	3,321.89	2,990.13	12,414.33
(f)	Others	8.03	11.01	12.74	40.77
	Total	20,790.21	18,105.63	20,212.35	75,279.38
	Less : Inter Segment Revenue	-	-	-	-
	Net Sales / Income from Operations	20,790.21	18,105.63	20,212.35	75,279.38
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]				
(a)	Animal Welfare	215.60	431.56	129.21	1,050.95
(b)	Consumer Products	603.77	381.97	498.46	1,621.59
(c)	Medical Devices	562.29	405.66	580.09	1,692.89
(d)	Protective Devices	(154.36)	560.02	302.59	1,595.52
(e)	Foods	108.59	(81.02)	3.99	(310.68)
(f)	Others	6.93	9.48	9.92	(64.74)
	Total	1,342.82	1,707.67	1,524.26	5,585.53
	Less : Finance Cost	85.79	92.96	85.99	275.55
	Less : Unallocable Expenses (Net of Unallocable Income)	(2,822.40)	(807.92)	(625.59)	(3,102.05)
	Total Profit (+) / Loss (-) before tax	4,079.43	2,422.63	2,063.86	8,412.03
		As on	As on	As on	As on
		30/06/2024	31/03/2024	30/06/2023	31/03/2024
3.	Segment Assets:				
(a)	Animal Welfare Division	3,925.91	3,999.99	4,166.46	3,999.99
(b)	Consumer Products	4,187.30	4,702.91	4,919.58	4,702.91
(c)	Medical Devices	6,633.64	6,409.49	7,079.53	6,409.49
(d)	Protective Devices	13,390.58	12,293.07	12,015.97	12,293.07
(e)	Foods	6,734.84	6,727.70	7,783.75	6,727.70
(f)	Others	287.61	281.56	242.70	281.56
	Total	35,159.88	34,414.72	36,207.99	34,414.72
	Unallocated	90,356.01	85,644.75	84,170.66	85,644.75
	Total Assets	1,25,515.89	1,20,059.47	1,20,378.65	1,20,059.47

4. Segment Liabilities:					
(a)	Animal Welfare Division	3,336.85	3,116.58	3,607.77	3,116.58
(b)	Consumer Products	6,916.36	6,970.15	7,184.74	6,970.15
(c)	Medical Devices	1,482.68	1,048.52	2,369.89	1,048.52
(d)	Protective Devices	4,166.46	3,631.64	4,385.33	3,631.64
(e)	Foods	1,540.76	1,623.88	1,505.53	1,623.88
(f)	Others	149.91	150.88	133.72	150.88
Total		17,593.02	16,541.65	19,186.98	16,541.65
Unallocated		4,484.00	3,425.93	4,194.19	3,425.93
Total Liabilities		22,077.02	19,967.58	23,381.17	19,967.58

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Animal Welfare comprise products for Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED


T.T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : August 02, 2024

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the year ended	
		(30/06/2024)	(31/03/2024)	(30/06/2023)	(31/03/2024)	
		Unaudited	Audited	Unaudited	Audited	
1.	Total income from Operations	20,790.21	18,105.63	20,212.35	75,279.38	
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	2,102.38	2,422.63	2,063.86	8,412.03	
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	4,079.43	2,422.63	2,063.86	8,412.03	
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	3,157.51	1,827.20	1,566.91	6,284.19	
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	3,346.98	1,627.14	1,659.07	6,166.51	
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	98,237.43	
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)					
	(a) Basic (in Rs.)	22.35	12.93	11.09	44.47	
	(b) Diluted (in Rs.)	22.35	12.93	11.09	44.47	

Notes:

- The above is an extract of the detailed Statement of Unaudited Financial Results for the First Quarter ended June 30, 2024, in respect of TTK Healthcare Limited (the Company) filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the First Quarter ended June 30, 2024 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- The above financial results for the First Quarter ended June 30, 2024 in respect of the Company have been reviewed by the Audit Committee at its meeting held on August 01, 2024 and approved by the Board of Directors of the Company at its meeting held on August 02, 2024 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- During the Quarter, the Company has sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
- Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable.
- The figures for the Quarter ended March 31, 2024 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive ChairmanPlace : Chennai
Date : August 02, 2024

Independent Auditor's Review Report on review of Interim financial results

To the Board of Directors of TTK Healthcare Limited

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and period ended 30th June 2024. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initiated by us for identification purposes.

Management's Responsibility

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

Attention is drawn to the fact that the figures for the quarter ended 31st March 2024 as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us.

Our conclusion is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018


S. Rajeshwari

Partner

Membership No. 024105



Place: Chennai

Date: 02nd August, 2024

UDIN No: **24024105BKAOEY5362**